Guía clara de 2026 sobre las demandas por parálisis estomacal (gastroparesia) y obstrucción intestinal vinculadas a Ozempic, Wegovy y Mounjaro. Conoce quién puede calificar, cómo funciona la consolidación MDL 3094, qué debes probar, la estructura de honorarios por contingencia y el plazo de prescripción.
A plain-English 2026 guide to the Ozempic, Wegovy and Mounjaro stomach paralysis (gastroparesis) and bowel obstruction lawsuits. Learn who may qualify, how MDL 3094 consolidation works, what you must prove, settlement and contingency-fee structure, and the statute of limitations.
Análisis de NVO Novo Nordisk para 2026. Franquicia Wegovy y Ozempic, ensayo CagriSema REDEFINE, competencia con LLY Eli Lilly, negociación de precios Medicare IRA, pipeline amycretin, y escenarios de valoración para inversores en LATAM y España.
NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.
NVO 노보 노디스크 주가 전망 2026년. Wegovy·Ozempic GLP-1 시장 지위, CagriSema REDEFINE 임상 결과, IRA 약가 협상 리스크, 아미크레틴 파이프라인, 한국 투자자 세금 전략까지 전문가 시각으로 분석합니다.
MDL 3094 — the GLP-1 gastroparesis and ileus mass tort in the Eastern District of Pennsylvania — has grown to 2,900+ cases. Here is what US plaintiffs need to know about eligibility, evidence, and the road ahead.